

AMENDMENT

In the Claims

Please cancel claims 68-75 and amend the remaining claims as indicated below:

18. (Amended) An anti-human antigen receptor, the receptor being low or not immunogenic in humans, the receptor being further characterized as comprising a human VH chain and a human VL chain wherein at least said VH chain is derived from essentially unprimed mature human B-lymphocytes and said VL chain is derived from a naturally occurring human B cell repertoire.

20. (Amended) The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, said anti-human antigen receptor recognizing a human tumor antigen.

21. (Amended) The anti-human antigen receptor according to any one of claims 18, 19, 65, 66 or 67, said anti-human antigen receptor recognizing the native human 17-1A antigen.

28. (Amended) An anti-human antigen receptor, said receptor being characterized in that it comprises a human VH chain and a human VL chain that have been functionally rearranged, said receptor recognizing the native human 17-1A antigen.

31. (Amended) The anti-human antigen receptor of claim 28 recognizing an epitope of the extracellular domain of the 17-1A antigen.

Handwritten: 32
32. (Amended) The anti-human antigen receptor of claim 28, wherein the VH chain comprises at least one of SEQ ID NOS: 143 and/or 145 and/or the VL chain comprises at least one of SEQ ID NOS: 141 and/or 147.

Handwritten: 65
65. (Amended) The anti-human antigen receptor according to claim 18, further comprising, fused to said human VH and VL chains, (a) the same or other VH or VL chains, (b) immunoglobulin constant regions of heavy (CH) or light chains (CL) or parts thereof, or (c) non-immunoglobulin chains, respectively.

Handwritten: 67
67. (Amended) The anti-human antigen receptor according to claim 18, further comprising linked to said human VH and VL chains a non-proteinous pharmaceutical and/or other biologically active molecule.